Two Fraction Prostate SBRT With DIL SIB

Recruiting now · Phase 1

Conditions studied: Prostate Cancer

In brief

Phase I/Ib, single arm trial of Two-Fraction Stereotactic Body Radiation Therapy (SBRT) with an MRI directed, dominant intraprostatic lesion (DIL), simultaneous integrated boost (SIB) based on genomic classification in the treatment of localized prostate cancer. The primary purpose of this study is to determine the feasibility and safety of two fraction SBRT in patients with localized prostate cancer.

Key facts

Study ID

NCT05864196

Run by

NYU Langone Health

People needed

80

Starts

2023-07-17

Expected to finish

2030-06-01

Last updated by the study team

2026-01-29

Who can join

Age: 18 and older. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

• Patient age greater than or equal 18
• Localized adenocarcinoma of the prostate
• Biopsy-proven diagnosis of prostate adenocarcinoma
• Low to intermediate risk National Comprehensive Cancer Network (NCCN) disease
• TX-T2c-8th addition staging
• PSA<20 ng/ml
• Grade group 3 or less
• Proper rectal space replacement required as determined by the treating radiation oncologist
• Prostate size less than 60cc defined at time of simulation based on MRI
• Patient ability to undergo MRI and documented dominant Prostate Imaging Reporting and Data System (PI-RADS) 3 or higher lesion
• - Exception is very low risk, low risk, or favorable intermediate risk with a low to intermediate decipher score in which case an SIB is not utilized
• Androgen-deprivation therapy (ADT) is left to the discretion of the treating radiation oncologist
• Agreement to use effective contraceptive methods such as condoms and spermicidal foam, intrauterine device, or for their partner to use prescription birth control pills
• Ability to give informed consent

You may not qualify if…

• High risk disease
• Pelvic lymph node involvement
• Prophylactic lymph node irradiation requirement as determined by the treating radiation oncologist
• Evidence of clinical or radiological extracapsular extension or seminal vesicle invasion
• Prior radiation to the pelvis
• Prior malignancies within the last 5 years
• Inability to meet pre-specified 2 fraction DVH constraints
• Prostate size > 60cc as measures at treatment planning MRI
• Active significant inflammatory bowel disease (IBD) or rheumatological disease
• Prior prostate surgeries
• Previous uro lift
• Transurethral resection of the prostate (TURP) within 6 months of SBRT
• "Reasonable" urinary, bowel, and erectile function as defined by the pre-treatment EPIC questionnaire (>50 overall summary score for each domain)
• Men of reproductive potential may not participate unless they agree to use an effective contraceptive method

Where it is running

• NYU Langone Hospital - Long Island — Mineola, New York, United States (enrolling)
• NYCyberKnife at Perlmutter Cancer Center — New York, New York, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.